Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis

Inclusion criteria: * Age ≥ 18 years * Patient willing to participate in the study * Patient with cancer receiving neoadjuvant, adjuvant, or maintenance treatment · Patient treated with ICI, either as monotherapy or in combination with another antitumor treatment (targeted therapy, chemotherapy, or radiotherapy), either de novo or after a first-line treatment including ICIs * Patient who has received at least one injection of an ICI · * Onset of hepatitis following treatment initiation, defined by the following criteria: * ALT (alanine aminotransferase) ≥ 5 times the upper normal limit * ALP (alkaline phosphatase) ≥ 2 times the upper normal limit * ALT (alanine aminotransferase) ≥ 3 times the upper normal limit and bilirubin ≥ 2 times the upper normal limit · * Patient with grade 3 or 4 hepatitis, according to the current CTCAE classification * Exclusion criteria: * Patient with another cause of acute hepatitis, including viral, autoimmune, ischemic, acute alcoholic hepatitis, or Wilson's disease. * Patient unable to express their non-opposition to participate in the study. * Person deprived of liberty, under guardianship or curatorship, or in an emergency situation. * Person not affiliated with a social security system or without entitlement to healthcare coverage.